Annals of Internal Medicine, Tip Sheet, November 7, 2000

November 06, 2000

Annals of Internal Medicine is published by the American College of Physicians-American Society of Internal Medicine (ACP-ASIM), an organization of more than 115,000 internal medicine physicians and medical students. The following highlights are not intended to substitute for articles as sources of information. For an embargoed fax of an article, call 1-800-523-1546, ext. 2656 or 215-351-2656. Full content of the issue is available on the Internet at on November 7, 2000.

Program Successfully Controls Anticoagulant Therapy In Elderly Patients

A rigorous controlled trial of a program to manage long-term warfarin therapy demonstrated that the program reduced frequency of major bleeding and more effectively maintained blood clotting levels in an acceptable range (Article, p. 687). The program consisted of assessing the patients' risks for bleeding, educating patients to monitor their blood clotting time at home, and managing the anticoagulant drug dosing using guidelines.

Study Proposes Immediate Treatment for Mild Hepatitis C

A cost-effectiveness analysis of treatment for mild chronic hepatitis C virus (HCV) compared immediate therapy with two antiviral drugs to watchful waiting and periodic liver biopsies plus later drug treatment (Article, p. 665). The study found that immediate antiviral therapy would increase survival and reduce costs for people with mild HCV.

CAPTURE, SHOCK: Clinical Trial Names and the "Branding" of Research

Until the 1970s, clinical trials didn't have ordinary names. But then came MRFIT, the Multiple Risk Factor Intervention Trial, that became affectionately known as Mr. Fit. A memorable moniker can encapsulate complex, concrete information in a single reference; it can carry soft and fuzzy meanings and associations as well. A physician describes the evolution of clinical trials naming from MRFIT to today's SCAT and SYMPHONY, MOCHA and COBRA, CAPTURE and SHOCK (Medical Writings, p. 755). He notes that the mnemonic names coincided with the rapid growth in sponsorship of clinical trials by pharmaceutical and biotechnology companies and that the "branding" of study groups and clinical trials may thus be "a manifestation of a marketing strategy that works well, perhaps too well, in other areas of medicine." He asks whose interests this "branding" of research really serves?

American College of Physicians

Related Clinical Trials Articles from Brightsurf:

Nearly 1 in 5 cancer patients less likely to enroll in clinical trials during pandemic
A significant portion of cancer patients may be less likely to enroll in a clinical trial due to the ongoing coronavirus pandemic.

COVID-19 clinical trials lack diversity
Despite disproportionately higher rates of COVID-19 infection, hospitalization and death among people of color, minority groups are significantly underrepresented in COVID-19 clinical trials.

Why we should trust registered clinical trials
In a time when we have to rely on clinical trials for COVID-19 drugs and vaccines, a new study brings good news about the credibility of registered clinical trials.

Inclusion of children in clinical trials of treatments for COVID-19
This Viewpoint discusses the exclusion of children from coronavirus disease 2019 (COVID-19) clinical trials and why that could harm treatment options for children.

Review evaluates how AI could boost the success of clinical trials
In a review publishing July 17, 2019 in the journal Trends in Pharmacological Sciences, researchers examined how artificial intelligence (AI) could affect drug development in the coming decade.

Kidney patients are neglected in clinical trials
The exclusion of patients with kidney diseases from clinical trials remains an unsolved problem that hinders optimal care of these patients.

Clinical trials beginning for possible preeclampsia treatment
For over 20 years, a team of researchers at Lund University has worked on developing a drug against preeclampsia -- a serious disorder which annually affects around 9 million pregnant women worldwide and is one of the main causes of death in both mothers and unborn babies.

Underenrollment in clinical trials: Patients not the problem
The authors of the study published this month in the Journal of Clinical Oncology investigated why many cancer clinical trials fail to enroll enough patients.

When designing clinical trials for huntington's disease, first ask the experts
Progress in understanding the genetic mutation responsible for Huntington's disease (HD) and at least some molecular underpinnings of the disease has resulted in a new era of clinical testing of potential treatments.

New ALS therapy in clinical trials
New research led by Washington University School of Medicine in St.

Read More: Clinical Trials News and Clinical Trials Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to